Physician profile
Leonardo Forero
NPI 1700847464
$11,330.20
in general payments reported to CMS, 2019-2025
37 companies · $94.39 in 2025
The $94.39 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,456 · 2020: $33.94 · 2021: $179 · 2022: $655 · 2023: $274 · 2024: $638 · 2025: $94.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $808 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $807.52 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $5,700.24 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $3,338.48 | 2019-2024 | |
| Astellas Pharma US INC | $402.18 | 2019-2023 | Xtandi |
| Seagen INC. | $319.26 | 2019-2022 | |
| Pfizer INC. | $265.47 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $141.00 | 2023-2024 | Tagrisso |
| Janssen Biotech, INC. | $121.84 | 2024 | Erleada, Akeega |
| Novartis Pharmaceuticals Corporation | $116.74 | 2019-2025 | |
| Sirtex Medical INC | $110.55 | 2019 | |
| Janssen Scientific Affairs, LLC | $98.60 | 2019-2020 | |
| Daiichi Sankyo INC. | $90.00 | 2024 | Enhertu |
| Novocure INC. | $76.01 | 2019 | |
| Lilly USA, LLC | $72.19 | 2019 | |
| Exelixis INC. | $65.30 | 2019-2025 | Cabometyx |
| Puma Biotechnology, INC. | $63.70 | 2019-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $47.53 | 2022-2023 | Proclaim |
| Karyopharm Therapeutics INC. | $36.39 | 2022 | |
| Genzyme Corporation | $32.07 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.54 | 2019-2020 | |
| Abbvie INC. | $28.89 | 2025 | |
| Foundation Medicine, INC. | $26.16 | 2019 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Immunogen, INC. | $17.38 | 2023 | Elahere |
| Amgen INC. | $16.48 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $16.46 | 2019 | |
| Genentech USA, INC. | $16.23 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.12 | 2021 | |
| Tactile Systems Technology INC | $12.98 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Tesaro, INC. | $11.36 | 2019 | |
| Clovis Oncology, INC. | $7.20 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonardo Forero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.